Yazar "Ozdemir, E." seçeneğine göre listele
Listeleniyor 1 - 6 / 6
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Antinociceptive Effects in Normal and Diabetic Rats Exposed to 50 Hz Magnetic Field(SPRINGER, 2012) Kosar, M. I.; Demir, T.; Demirkazik, A.; Deveci, K.; Ozdemir, E.; Gulturk, S.The effects of repeated applications of alternating sinusoidal 50 Hz magnetic field, MF (B = 5.0 mT, 165-min-long sessions everyday, each including four 30-min-long exposures separated by 15-min-long intervals, carried out for 30 days), on thermonociception (estimated using the tail-flick test) were examined in intact rats, diabetic rats (induction by streptozotocin), and diabetic rats treated with insulin. Exposures to MF led to mild (several percent) increases in the tail-flick latency, TFL, immediately after each session and a sustained rather significant rise in this parameter (increment up to 40%) developing with some delay, from 2 to 4 days. The latter effect was limited in time (lasting 2 days long); then, the TFLs tended to rapidly return to initial (or nearly initial) values. This intense hypoalgesic effect induced by MF exposures was observed on days 3 and 4 in normal rats, on days 4 and 5 in diabetic rats, and on days 5 and 6 in diabetic rats treated with insulin. Significant increases in the mean arterial blood pressure were observed in diabetic rats; exposures to MF exerted no significant influence on this parameter in both normal and diabetic animals. Mechanisms of the development of diabetic neuropathy and those of the hypoalgesic actions of MF are discussed. The MF-induced antinociception seems to be, in future, an attractive choice for the relief of acute and chronic symptoms in diabetic neuropathy, but further detailed studies are necessary to find optimum MF parameters, modes of application, and "time windows."Öğe Effects of fluoxetine and LY 365265 on tolerance to the analgesic effect of morphine in rats(AKADEMIAI KIADO ZRT, 2011) Ozdemir, E.; Bagcivan, I.; Gursoy, S.; Altun, A.; Durmus, N.Morphine is widely used to treat chronic pain, however its utility is hindered by the development of tolerance to its analgesic effects. The aim of this study was to investigate effects of fluoxetine, a specific serotonin (5-HT) reuptake inhibitor, and LY 367265, an inhibitor of the 5-HT transporter and 5-HT2A receptor antagonist, on tolerance induced to the analgesic effect of morphine in rats. The study was carried out on male Wistar Albino rats (weighing 170-190 g). To constitute morphine tolerance, animals received morphine (50 mg/kg; s.c.) once daily for 3 days. After last dose of morphine, injected on day 4, morphine tolerance was evaluated. The analgesic effects of fluoxetine (10 mg/kg; i.p.), LY 367265 (3 mg/kg; i.p.) and morphine were considered at 30-min intervals by tail-flick and hot-plate tests. The results showed that fluoxetine and LY 367265 significantly attenuated the development and expression of morphine tolerance. The maximal antinociceptive effects were obtained 30 min after administration of fluoxetine and 60 min after administration of LY 367265. In conclusion, we observed that co-injection of morphine with fluoxetine and LY 367265 increased the analgesic effects of morphine and delayed development of tolerance to morphine analgesia.Öğe Effects of Magnesium on Behavior, iNOS, nNOS and eNOS Expression in Male Rats Exposed to Anxiety(Wiley, 2019) Cetin, A.; Karabulut, S.; Taskiran, A. S.; Ergul, M.; Ozdemir, E.[Abstract Not Available]Öğe Expression of Serum Vascular Endothelial Growth Factor and Angiopoietin Receptor Tie-2 in Essential Hypertension(Univ West Indies Faculty Medical Sciences, 2022) Filiz, A. K.; Ozdemir, E.; Gunes, H.; Yilmaz, M. B.Objective: To investigate the serum levels of a vascular endothelial growth factor (VEGF), an angiogenic factor and a soluble angiopoietin receptor Tie-2 (sTie-2) in patients with essential hypertension. Methods: In the present study 90 individuals (56 males and 34 females, mean age 48 +/- 7 years) have been divided into 3 groups: 30 patients with hypertension, 30 healthy individuals with a family history of hypertension and 30 healthy individuals with no family history of hypertension. All individuals have been evaluated in terms of blood pressure and biochemical parameters. The levels of VEGF and Tie-2 receptor have been evaluated by using the enzyme-linked immunosorbent assay method. Results: The findings suggested that the serum VEGF, sTie-2 receptor; low-density lipoprotein and triglycerides levels in the hypertensive patients were significantly higher than those in the control group (p < 0.05). However, the level of high-density lipoprotein cholesterol in the patients was significantly lower than in those in the control group (p < 0.05). In correlation analysis, a positive correlation was found statistically significant between the values of VEGF and sTie-2 (r = 0.405, p = 0.026). Conclusion: As a result of this study, our data indicate that serum levels of VEGF and Tie-2 receptor may be related to the primary hypertension. This study could inspire to further studies to explore the roles of VEGF and Tie-2 receptor in essential hypertension.Öğe Modulation of Morphine Analgesia and Tolerance in Rats by NMDA Receptor Antagonists(SPRINGER, 2012) Ozdemir, E.; Bagcivan, I.; Gursoy, S.The efficacy of opioids in chronic pain treatment is limited because of the development of opioid tolerance. We investigated the role of N-methyl-D-aspartate (NMDA) receptor antagonists (NMDAR Ants) in morphine analgesia and tolerance in rats. To induce the morphine tolerance, experimental rats received morphine (50 mg/kg; subcutaneously) once daily for 3 days. After the last dose of morphine was injected on day 4 and morphine tolerance was evaluated, analgesic effects of ketamine, dizocilpine (MK-801, a non-competitive NMDAR Ant), LY235959 (a competitive NMDAR Ant), cis-2,3-piperidinedicarboxylic acid (PDA, an NMDAR agonist), and morphine were estimated with 30-min-long intervals (0, 30, 60, 90, and 120 min) by the tail-flick and hot-plate algesia tests (n = 6 in each studied group). As was found, ketamine, MK-801, and LY235959 significantly attenuated the development of morphine tolerance (P < 0.05). On the other hand, PDA somewhat increased the development of this tolerance, but the difference was not statistically significant (P > 0.05). Our data indicate that NMDAR Ants attenuate the development of morphine tolerance, significantly affecting the effects of morphine analgesia in rats.Öğe Soluble guanylyl cyclase activators increase the expression of tolerance to morphine analgesic effect(COMENIUS UNIV, 2014) Durmus, N.; Bagcivan, I; Ozdemir, E.; Altun, A.; Gursoy, S.Objectives: It is aimed to investigate the effects of guanylyl cyclase activation and inhibition on acute morphine antinociception and the development of tolerance to its effect. Background: Nitric oxide-soluble guanylyl cyclase signal transduction cascade suggested to play an important role in the development of tolerance to antinociceptive effects of morphine. Methods: Nociception was evaluated by tail flick and hot plate tests in male Wistar rats. The analgesic effects of intraperitoneal protoporphyrin IX (PPIX; an activator of soluble guanylyl cyclase), 3-morpholinosydnonimine hydrochloride (SIN-1; NO donor and activator of guanylyl cyclase), S-Nitroso-N-acetylpenicillamine (SNAP; an activator of guanylyl cyclase), 3,3-Bis (amino ethyl)-1-hydroxy-2-oxo-l-triazene (NOC-18; NO donor activating guanylyl cyclase) and 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-l-one (ODQ; an inhibitor of guanylyl cyclase) alone or in combination with subcutaneous morphine injection were evaluated. Their effects on morphine tolerance development were evaluated by giving these agents 20 minutes prior to twice daily morphine injection during tolerance development for 5 days. On day 6, the expression of morphine tolerance was determined. Results: PPIX, SIN-1, SNAP and NOC-18 significantly increased expression of morphine tolerance while ODQ decreased. Conclusion: These data suggested that sGC activators have a significant role in tolerance to the analgesic effect of morphine (Tab. 1, Fig. 4, Ref. 29). Text in PDF www.elis.sk.
